FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387379432> ?p ?o ?g. }

• W4387379432 abstract "Abstract Disclosure: J. Poon: Employee; Self; Eli Lilly & Company. Stock Owner; Self; Eli Lilly & Company. S. Zhang: Employee; Self; Eli Lilly & Company. Stock Owner; Self; Eli Lilly & Company. H. Kan: Employee; Self; Eli Lilly & Company. Stock Owner; Self; Eli Lilly & Company. M.C. Bunck: Employee; Self; Eli Lilly & Company. Stock Owner; Self; Eli Lilly & Company. J. Dunn: Employee; Self; Eli Lilly & Company. Stock Owner; Self; Eli Lilly & Company. A. Stefanski: Employee; Self; Eli Lilly & Company. Stock Owner; Self; Eli Lilly & Company. M. Murphy: Employee; Self; Eli Lilly & Company. Stock Owner; Self; Eli Lilly & Company. Background: Living with obesity negatively impacts a person’s mental health and psychosocial function, leading to impaired health-related quality of life (HRQoL). Tirzepatide resulted in clinically sustained reductions in body weight among participants with obesity in SURMOUNT-1, a Phase 3 randomized clinical trial. To determine the impact of tirzepatide treatment on mental health and psychosocial function, changes in HRQoL were assessed in SURMOUNT-1 using the Short Form 36 health survey version 2 acute form (SF-36v2) and the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT). Methods: A total of 2,539 participants were included in the study (tirzepatide 5 mg, N=630; 10 mg, N=636; 15 mg, N=630; placebo, N=643). The SF-36v2 (36 items) and IWQOL-Lite-CT (20 items) were collected at both baseline and endpoint of primary treatment period (week 72 or early discontinuation, where last observation was carried forward (LOCF)). The SF-36v2 assesses eight domains of HRQoL including role-emotional and mental health, and yields two additional summary scores, including the Mental Component Summary (MCS) score. SF-36v2 scores are norm-based with mean (SD) 50 (10). IWQOL-Lite-CT assesses three primary composites, including 13-item psychosocial composite score. IWQOL-Lite-CT composite scores were transformed to a scale of 0 to 100. Higher scores of both SF-36v2 and IWQOL-Lite-CT indicates better levels of health and psychosocial function. Estimated mean change from baseline to week 72 for SF-36v2 (norm-based) and IWQOL-Lite-CT composite (transformed) scores were analyzed using an analysis of covariance (ANCOVA) model. Results: Mean scores at baseline for tirzepatide 5, 10, 15 mg doses and placebo for SF-36v2 role-emotional were 50.7, 51.0, 50.5, and 50.8, respectively, and for mental health were 53.4, 54.0, 53.4, and 53.4, respectively. Mean MCS scores at baseline for tirzepatide 5, 10, 15 mg doses and placebo were 53.3, 53.8, 53.4, and 53.5, respectively. Mean scores at baseline for tirzepatide 5, 10, 15 mg doses and placebo for IWQOL-Lite-CT psychosocial composite score were 64.3, 62.1, 63.2, and 63.2, respectively. All doses of tirzepatide showed significant improvements at week 72 compared to placebo for both SF-36v2 and IWQOL-Lite-CT scores (p&lt;0.05). Estimated mean change from baseline to week 72 with tirzepatide 5, 10, 15 mg doses versus placebo were as follows: SF-36v2 role-emotional scores, 1.7, 1.3, and 1.8, versus 0.3 (p&lt;0.05); SF-36v2 mental health scores 0.8, 0.8, and 1.1, versus -0.2 (p&lt;0.05); SF-36v2 MCS scores were 0.7, 0.4, and 0.7 versus -0.5 (p&lt;0.05); IWQOL-Lite-CT psychosocial scores 19.6, 22.1, and 23.6 versus 11.0 (p&lt;0.001). Conclusion: In SURMOUNT-1, tirzepatide demonstrated statistically significant improvements in patient-reported mental health and psychosocial function as assessed by SF-36v2 and IWQOL-Lite-CT, compared to placebo. Presentation: Friday, June 16, 2023" @default.
• W4387379432 created "2023-10-06" @default.
• W4387379432 creator A5017401077 @default.
• W4387379432 creator A5045882614 @default.
• W4387379432 creator A5046839756 @default.
• W4387379432 creator A5048405172 @default.
• W4387379432 creator A5061814849 @default.
• W4387379432 creator A5071090995 @default.
• W4387379432 creator A5080576431 @default.
• W4387379432 date "2023-10-01" @default.
• W4387379432 modified "2023-10-16" @default.
• W4387379432 title "OR10-05 Improved Mental And Psychosocial Patient-Reported Outcomes Among People With Obesity Treated With Tirzepatide: Results From SURMOUNT-1 Study" @default.
• W4387379432 doi "https://doi.org/10.1210/jendso/bvad114.011" @default.
• W4387379432 hasPublicationYear "2023" @default.
• W4387379432 type Work @default.
• W4387379432 citedByCount "0" @default.
• W4387379432 crossrefType "journal-article" @default.
• W4387379432 hasAuthorship W4387379432A5017401077 @default.
• W4387379432 hasAuthorship W4387379432A5045882614 @default.
• W4387379432 hasAuthorship W4387379432A5046839756 @default.
• W4387379432 hasAuthorship W4387379432A5048405172 @default.
• W4387379432 hasAuthorship W4387379432A5061814849 @default.
• W4387379432 hasAuthorship W4387379432A5071090995 @default.
• W4387379432 hasAuthorship W4387379432A5080576431 @default.
• W4387379432 hasBestOaLocation W43873794321 @default.
• W4387379432 hasConcept C10138342 @default.
• W4387379432 hasConcept C118552586 @default.
• W4387379432 hasConcept C127413603 @default.
• W4387379432 hasConcept C144133560 @default.
• W4387379432 hasConcept C150966472 @default.
• W4387379432 hasConcept C15744967 @default.
• W4387379432 hasConcept C162324750 @default.
• W4387379432 hasConcept C187736073 @default.
• W4387379432 hasConcept C204036174 @default.
• W4387379432 hasConcept C3017619653 @default.
• W4387379432 hasConcept C71924100 @default.
• W4387379432 hasConcept C74909509 @default.
• W4387379432 hasConcept C78519656 @default.
• W4387379432 hasConceptScore W4387379432C10138342 @default.
• W4387379432 hasConceptScore W4387379432C118552586 @default.
• W4387379432 hasConceptScore W4387379432C127413603 @default.
• W4387379432 hasConceptScore W4387379432C144133560 @default.
• W4387379432 hasConceptScore W4387379432C150966472 @default.
• W4387379432 hasConceptScore W4387379432C15744967 @default.
• W4387379432 hasConceptScore W4387379432C162324750 @default.
• W4387379432 hasConceptScore W4387379432C187736073 @default.
• W4387379432 hasConceptScore W4387379432C204036174 @default.
• W4387379432 hasConceptScore W4387379432C3017619653 @default.
• W4387379432 hasConceptScore W4387379432C71924100 @default.
• W4387379432 hasConceptScore W4387379432C74909509 @default.
• W4387379432 hasConceptScore W4387379432C78519656 @default.
• W4387379432 hasIssue "Supplement_1" @default.
• W4387379432 hasLocation W43873794321 @default.
• W4387379432 hasOpenAccess W4387379432 @default.
• W4387379432 hasPrimaryLocation W43873794321 @default.
• W4387379432 hasRelatedWork W1913123124 @default.
• W4387379432 hasRelatedWork W1986077376 @default.
• W4387379432 hasRelatedWork W2032387653 @default.
• W4387379432 hasRelatedWork W2083246719 @default.
• W4387379432 hasRelatedWork W2163175145 @default.
• W4387379432 hasRelatedWork W2269717656 @default.
• W4387379432 hasRelatedWork W2400067849 @default.
• W4387379432 hasRelatedWork W2600710334 @default.
• W4387379432 hasRelatedWork W2735604125 @default.
• W4387379432 hasRelatedWork W2511633412 @default.
• W4387379432 hasVolume "7" @default.
• W4387379432 isParatext "false" @default.
• W4387379432 isRetracted "false" @default.
• W4387379432 workType "article" @default.